|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.68 USD | -2.34% |
|
+0.25% | -22.51% |
| Jun. 04 | AlphaValue/Baader Europe Cuts Qiagen Price Target, Estimates Post FY26 Guidance Change | MT |
| Jun. 03 | Qiagen N.V. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 11:40 AM |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 6.84 | 5.8 | 4.49 | 5.24 | 5.77 | |||||
Return on Total Capital | 8.24 | 6.8 | 5.07 | 5.84 | 6.46 | |||||
Return On Equity % | 17.39 | 12.9 | 9.38 | 2.27 | 11.57 | |||||
Return on Common Equity | 17.39 | 12.9 | 9.38 | 2.27 | 11.57 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 67.41 | 67.5 | 66.04 | 66.77 | 66.36 | |||||
SG&A Margin | 25.96 | 28.2 | 29.47 | 28.53 | 27.93 | |||||
EBITDA Margin % | 38.35 | 36.15 | 32.51 | 34.64 | 34.85 | |||||
EBITA Margin % | 33.85 | 31.3 | 27.43 | 29.31 | 29.8 | |||||
EBIT Margin % | 29.22 | 26.93 | 22.66 | 25.02 | 26.44 | |||||
Income From Continuing Operations Margin % | 22.77 | 19.76 | 17.37 | 4.23 | 20.33 | |||||
Net Income Margin % | 22.77 | 19.76 | 17.37 | 4.23 | 20.33 | |||||
Net Avail. For Common Margin % | 22.77 | 19.76 | 17.37 | 4.23 | 20.33 | |||||
Normalized Net Income Margin | 17.12 | 16.28 | 14.92 | 16.46 | 17.33 | |||||
Levered Free Cash Flow Margin | 20.55 | 20.91 | 7.98 | 33.15 | 12.3 | |||||
Unlevered Free Cash Flow Margin | 20.63 | 21.04 | 8.15 | 33.6 | 13.13 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.37 | 0.34 | 0.32 | 0.34 | 0.35 | |||||
Fixed Assets Turnover | 3.21 | 2.86 | 2.41 | 2.27 | 2.15 | |||||
Receivables Turnover (Average Receivables) | 5.88 | 6.03 | 5.38 | 5.2 | 5.38 | |||||
Inventory Turnover (Average Inventory) | 2.37 | 2.03 | 1.76 | 1.94 | 2.42 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.39 | 2.46 | 1.99 | 3.61 | 3.9 | |||||
Quick Ratio | 0.99 | 1.87 | 1.44 | 2.93 | 3.13 | |||||
Operating Cash Flow to Current Liabilities | 0.42 | 0.73 | 0.43 | 1.24 | 1.28 | |||||
Days Sales Outstanding (Average Receivables) | 62.03 | 60.48 | 67.83 | 70.37 | 67.81 | |||||
Days Outstanding Inventory (Average Inventory) | 153.89 | 179.72 | 206.81 | 188.67 | 150.86 | |||||
Average Days Payable Outstanding | 51.99 | 50.23 | 47.15 | 56.94 | 39.21 | |||||
Cash Conversion Cycle (Average Days) | 163.93 | 189.98 | 227.49 | 202.11 | 179.45 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 65.91 | 57.46 | 44.91 | 42.4 | 48.56 | |||||
Total Debt / Total Capital | 39.73 | 36.49 | 30.99 | 29.78 | 32.69 | |||||
LT Debt/Equity | 37.83 | 45.59 | 28.88 | 40.22 | 47.32 | |||||
Long-Term Debt / Total Capital | 22.8 | 28.95 | 19.93 | 28.24 | 31.85 | |||||
Total Liabilities / Total Assets | 49.62 | 44.87 | 37.73 | 37.3 | 39.85 | |||||
EBIT / Interest Expense | 12.08 | 9.88 | 8.34 | 11.29 | 16.61 | |||||
EBITDA / Interest Expense | 16.35 | 13.73 | 12.5 | 16.33 | 22.75 | |||||
(EBITDA - Capex) / Interest Expense | 12.87 | 11.52 | 9.69 | 12.51 | 16.7 | |||||
Total Debt / EBITDA | 2.29 | 2.49 | 2.56 | 2.11 | 2.43 | |||||
Net Debt / EBITDA | 1.1 | 0.72 | 0.98 | 0.5 | 0.97 | |||||
Total Debt / (EBITDA - Capex) | 2.91 | 2.96 | 3.3 | 2.76 | 3.3 | |||||
Net Debt / (EBITDA - Capex) | 1.39 | 0.85 | 1.26 | 0.66 | 1.32 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 20.39 | -4.89 | -8.23 | 0.66 | 5.65 | |||||
Gross Profit, 1 Yr. Growth % | 17.14 | -4.78 | -10.21 | 1.78 | 4.99 | |||||
EBITDA, 1 Yr. Growth % | 17.48 | -10.35 | -17.48 | 7.25 | 6.28 | |||||
EBITA, 1 Yr. Growth % | 18.97 | -12.05 | -19.59 | 7.57 | 7.42 | |||||
EBIT, 1 Yr. Growth % | 22.4 | -12.35 | -22.78 | 11.16 | 11.63 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 42.71 | -17.44 | -19.35 | -75.51 | 408.28 | |||||
Net Income, 1 Yr. Growth % | 42.71 | -17.44 | -19.35 | -75.51 | 408.28 | |||||
Normalized Net Income, 1 Yr. Growth % | 29.14 | 8.35 | -15.86 | 11.03 | 11.2 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 44.44 | -16.74 | -19.56 | -75.75 | 409.76 | |||||
Accounts Receivable, 1 Yr. Growth % | -3.3 | -11.35 | 19.01 | -8.34 | 13.46 | |||||
Inventory, 1 Yr. Growth % | 12.48 | 9.29 | 11.29 | -29.9 | 8.1 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 11.66 | 2.52 | 14.86 | -0.05 | 23.83 | |||||
Total Assets, 1 Yr. Growth % | 4.72 | 2.29 | -2.74 | -6.96 | 10.4 | |||||
Tangible Book Value, 1 Yr. Growth % | -140.48 | 380.98 | 41.45 | 4.09 | -17.54 | |||||
Common Equity, 1 Yr. Growth % | 10.68 | 11.95 | 9.84 | -6.31 | 5.91 | |||||
Cash From Operations, 1 Yr. Growth % | 39.58 | 11.93 | -35.76 | 46.6 | -2.85 | |||||
Capital Expenditures, 1 Yr. Growth % | 43.01 | -31.95 | 15.85 | 11.67 | 20.26 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 1K | 1.47 | -47.98 | 317.9 | -61.83 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 948.39 | 1.69 | -47.4 | 315.1 | -59.78 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 21.45 | 7 | -6.57 | -3.89 | 3.12 | |||||
Gross Profit, 2 Yr. CAGR % | 18.73 | 5.61 | -7.53 | -4.4 | 3.37 | |||||
EBITDA, 2 Yr. CAGR % | 31.3 | 2.63 | -13.99 | -5.92 | 6.77 | |||||
EBITA, 2 Yr. CAGR % | 36.29 | 2.29 | -15.91 | 0.28 | 18.28 | |||||
EBIT, 2 Yr. CAGR % | 51.2 | 3.58 | -17.73 | -7.35 | 11.4 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 251.64 | 8.55 | -18.4 | -55.56 | 11.57 | |||||
Net Income, 2 Yr. CAGR % | 251.64 | 8.55 | -18.4 | -55.56 | 11.57 | |||||
Normalized Net Income, 2 Yr. CAGR % | 60.15 | -3.03 | -13.09 | -3.35 | 11.62 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 247.7 | 9.66 | -18.17 | -55.84 | 11.18 | |||||
Accounts Receivable, 2 Yr. CAGR % | -1.86 | -7.41 | 2.71 | 4.44 | 1.98 | |||||
Inventory, 2 Yr. CAGR % | 38.52 | 10.88 | 10.29 | -11.68 | -12.95 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 20.08 | 19.73 | 21.37 | 7.15 | 11.25 | |||||
Total Assets, 2 Yr. CAGR % | 8.35 | 2.99 | -0.76 | -4.88 | 1.35 | |||||
Tangible Book Value, 2 Yr. CAGR % | -29.24 | -13.7 | 66.11 | 21.34 | -7.36 | |||||
Common Equity, 2 Yr. CAGR % | 10.49 | 18.16 | 15.41 | 1.44 | -0.39 | |||||
Cash From Operations, 2 Yr. CAGR % | 38.98 | 24.99 | -15.2 | -2.96 | 19.34 | |||||
Capital Expenditures, 2 Yr. CAGR % | 26.89 | -1.35 | -11.21 | 13.74 | 15.88 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 20.28 | 161.69 | -48.32 | 47.44 | 28.01 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 19.46 | 158.09 | -47.87 | 47.76 | 30.93 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 14.45 | 11.95 | 1.66 | -4.22 | -0.81 | |||||
Gross Profit, 3 Yr. CAGR % | 12.74 | 10.31 | 0.05 | -4.53 | -1.37 | |||||
EBITDA, 3 Yr. CAGR % | 20.46 | 15.62 | -4.57 | -7.42 | -2.02 | |||||
EBITA, 3 Yr. CAGR % | 21.64 | 17.77 | -5.6 | -8.71 | 2.61 | |||||
EBIT, 3 Yr. CAGR % | 29.23 | 26.08 | -6.08 | -9.05 | -1.41 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 39.12 | 116.93 | -1.69 | -45.37 | 0.13 | |||||
Net Income, 3 Yr. CAGR % | 39.12 | 116.93 | -1.69 | -45.37 | 0.13 | |||||
Normalized Net Income, 3 Yr. CAGR % | 33.01 | 32.37 | -7.51 | -5.7 | 1.28 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 39.16 | 115.91 | -1.1 | -45.44 | -0.19 | |||||
Accounts Receivable, 3 Yr. CAGR % | 2.28 | -5.13 | 0.67 | -1.11 | 7.36 | |||||
Inventory, 3 Yr. CAGR % | 26.21 | 28 | 11.01 | -5.18 | -5.52 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 13.04 | 13.92 | 18.08 | 13.76 | 12.44 | |||||
Total Assets, 3 Yr. CAGR % | 2.26 | 6.29 | 1.04 | -2.87 | -0.03 | |||||
Tangible Book Value, 3 Yr. CAGR % | 32.06 | 34.04 | 1.75 | 42.15 | 6.68 | |||||
Common Equity, 3 Yr. CAGR % | 5.53 | 10.97 | 15.32 | 7.66 | 2.91 | |||||
Cash From Operations, 3 Yr. CAGR % | 21.13 | 29.3 | 0.12 | 1.77 | -2.92 | |||||
Capital Expenditures, 3 Yr. CAGR % | 20.05 | 3.09 | 4.08 | -4.16 | 15.87 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 16.21 | 11.87 | 33.88 | 3.73 | -5.19 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 15.51 | 11.46 | 33.28 | 4.1 | -3.39 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 10.97 | 8.6 | 5.53 | 5.32 | 2.25 | |||||
Gross Profit, 5 Yr. CAGR % | 12.12 | 7.6 | 4.15 | 4.17 | 1.37 | |||||
EBITDA, 5 Yr. CAGR % | 16.53 | 12.14 | 5.27 | 6.47 | -0.19 | |||||
EBITA, 5 Yr. CAGR % | 17.8 | 12.76 | 4.94 | 7.16 | -0.56 | |||||
EBIT, 5 Yr. CAGR % | 27.13 | 19.77 | 7.87 | 11.46 | 0.55 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 44.88 | 59.97 | 12.38 | 15.06 | 3.42 | |||||
Net Income, 5 Yr. CAGR % | 44.84 | 59.97 | 12.38 | 15.06 | 3.42 | |||||
Normalized Net Income, 5 Yr. CAGR % | 29.82 | 23.2 | 12.36 | 16.72 | -0.47 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 44.31 | 61.01 | 12.54 | 14.45 | 3.64 | |||||
Accounts Receivable, 5 Yr. CAGR % | 6.22 | 0.26 | 2.45 | -1.41 | 1.19 | |||||
Inventory, 5 Yr. CAGR % | 19.12 | 18.08 | 19.58 | 10.34 | 0.72 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 11.1 | 8.92 | 11.21 | 11.16 | 15.3 | |||||
Total Assets, 5 Yr. CAGR % | 7.37 | 4.53 | 1.24 | 1.68 | 1.16 | |||||
Tangible Book Value, 5 Yr. CAGR % | -1 | 81.66 | 73.38 | 28.81 | -1.99 | |||||
Common Equity, 5 Yr. CAGR % | 3.5 | 6.41 | 7.64 | 7.06 | 8.76 | |||||
Cash From Operations, 5 Yr. CAGR % | 13.34 | 20.06 | 5.03 | 15.28 | 7.4 | |||||
Capital Expenditures, 5 Yr. CAGR % | 20.57 | 7.48 | 6.4 | 7.22 | 8.65 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 6.2 | 23.39 | -11.85 | 15.44 | 31.5 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 6.04 | 22.57 | -11.88 | 15.35 | 32.33 |
- Stock Market
- Equities
- QGEN Stock
- Financials Qiagen N.V.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















